Opinions
Ian Nakamoto
Bausch & Lomb Inc.
BOL-N
DON'T BUY
Nov 07, 2006
Have been under investigation by the FCC. Also had some product defect.
$52.500
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Has gone through a transition. Was suffering a few years ago when it lost its momentum, R&D lagged. Can see some growth opportunity in their new lens. New president has shaken down the company, cut costs and re-invigorated their R&D. Has exceeded expectations for 13 quarters.
biotechnology
pharmaceutical
Advertising